在癌症临床试验中，Delta 样配体 4 抑制剂药物治疗会诱发肺动脉高压。

IF 2.2 4区医学 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS

Pulmonary Circulation Pub Date : 2024-11-08 eCollection Date: 2024-10-01 DOI:10.1002/pul2.12450

Casandra E Besse, Nolan M Winicki, Cristian Puerta, Moises Hernandez, Jason X-J Yuan, Patricia A Thistlethwaite

{"title":"在癌症临床试验中，Delta 样配体 4 抑制剂药物治疗会诱发肺动脉高压。","authors":"Casandra E Besse, Nolan M Winicki, Cristian Puerta, Moises Hernandez, Jason X-J Yuan, Patricia A Thistlethwaite","doi":"10.1002/pul2.12450","DOIUrl":null,"url":null,"abstract":"Delta-like ligand 4 (DLL-4) inhibitor drugs are an emerging cancer treatment. In clinical trials for solid organ malignancies, intravenous administration of monoclonal antibodies that inhibit DLL-4 is associated with development of pulmonary hypertension, in the absence of left ventricular dysfunction. Analysis of 13 clinical trials showed that pulmonary hypertension is a complication of DLL-4 inhibition.","PeriodicalId":20927,"journal":{"name":"Pulmonary Circulation","volume":"14 4","pages":"e12450"},"PeriodicalIF":2.2000,"publicationDate":"2024-11-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11544561/pdf/","citationCount":"0","resultStr":"{\"title\":\"Delta-like ligand 4 inhibitor drug treatment induces pulmonary hypertension in cancer clinical trials.\",\"authors\":\"Casandra E Besse, Nolan M Winicki, Cristian Puerta, Moises Hernandez, Jason X-J Yuan, Patricia A Thistlethwaite\",\"doi\":\"10.1002/pul2.12450\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Delta-like ligand 4 (DLL-4) inhibitor drugs are an emerging cancer treatment. In clinical trials for solid organ malignancies, intravenous administration of monoclonal antibodies that inhibit DLL-4 is associated with development of pulmonary hypertension, in the absence of left ventricular dysfunction. Analysis of 13 clinical trials showed that pulmonary hypertension is a complication of DLL-4 inhibition.\",\"PeriodicalId\":20927,\"journal\":{\"name\":\"Pulmonary Circulation\",\"volume\":\"14 4\",\"pages\":\"e12450\"},\"PeriodicalIF\":2.2000,\"publicationDate\":\"2024-11-08\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11544561/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Pulmonary Circulation\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1002/pul2.12450\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/10/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q2\",\"JCRName\":\"CARDIAC & CARDIOVASCULAR SYSTEMS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pulmonary Circulation","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1002/pul2.12450","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/10/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}

引用次数: 0

摘要

δ样配体 4（DLL-4）抑制剂药物是一种新兴的癌症治疗方法。在治疗实体器官恶性肿瘤的临床试验中，静脉注射抑制 DLL-4 的单克隆抗体与肺动脉高压的发生有关，但没有出现左心室功能障碍。对13项临床试验的分析表明，肺动脉高压是抑制DLL-4的并发症之一。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Delta-like ligand 4 inhibitor drug treatment induces pulmonary hypertension in cancer clinical trials.

Delta-like ligand 4 (DLL-4) inhibitor drugs are an emerging cancer treatment. In clinical trials for solid organ malignancies, intravenous administration of monoclonal antibodies that inhibit DLL-4 is associated with development of pulmonary hypertension, in the absence of left ventricular dysfunction. Analysis of 13 clinical trials showed that pulmonary hypertension is a complication of DLL-4 inhibition.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Pulmonary Circulation Medicine-Pulmonary and Respiratory Medicine

CiteScore

4.20

自引率

11.50%

发文量

153

审稿时长

15 weeks

期刊介绍： Pulmonary Circulation''s main goal is to encourage basic, translational, and clinical research by investigators, physician-scientists, and clinicans, in the hope of increasing survival rates for pulmonary hypertension and other pulmonary vascular diseases worldwide, and developing new therapeutic approaches for the diseases. Freely available online, Pulmonary Circulation allows diverse knowledge of research, techniques, and case studies to reach a wide readership of specialists in order to improve patient care and treatment outcomes.